Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 15;129(10):1465-1466.
doi: 10.1002/cncr.34810.

FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma

Mary Beth Nierengarten
Free article

FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma

Mary Beth Nierengarten. Cancer. .
Free article
No abstract available

PubMed Disclaimer

References

    1. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma. News release. US Food and Drug Administration. December 22, 2022. Accessed March 21, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grant...
    1. Budde LE , Sehn LH , Matasar M , et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-1065. doi:10.1016/S1470-2045(22)00335-7
    1. Bartlett NL , Sehn LH , Matasar MJ , et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received >2 prior therapies: updated results from the pivotal phase II study [abstract 610]. Abstract presented at: 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, LA. https://ash.confex.com/ash/2022/webprogram/Paper157691.html

MeSH terms

Substances

LinkOut - more resources